European Headache Federation publishes CGRP therapy guidelines

New guidance from the European Headache Federation has concluded that CGRP monoclonal antibodies are promising agents for migraine prevention, though real-world data will be important to support their efficacy and safety, especially in the long term. Biomarker research is also needed to identify patients most likely to respond.

Read more »

Alder files for US approval of eptinezumab

Alder Pharmaceuticals has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of eptinezumab in migraine prevention. If approved, the company plans to launch the drug in early 2020.

Read more »

Emgality (galcanezumab) receives US priority review for episodic cluster headache prevention

Emgality (galcanezumab) is undergoing Priority Review by the US Food and Drug Administration (FDA) for the preventive treatment of episodic cluster headache in adults. This follows the Breakthrough Therapy Designation that the drug received from the FDA for the indication in September 2018.

Read more »

Normal CGRP levels reported in patients with medication-overuse headache

New data showing normal levels of CGRP and nociceptin in patients with medication-overuse headache (MOH) underline the importance of identifying and treating MOH in patients with chronic headache.

Read more »

For all the other recent migraine news featured on the CGRP Forum click here »